Targeted therapies: Treating advanced kidney cancer - Miles to go before we sleep

Nature Reviews Clinical Oncology

Volumn 10, Issue 11, 2013, Pages 614-615

  Linehan, W Marston ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; PAZOPANIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ARTICLE; BAP1 GENE; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; MOUTH PAIN; ONCOGENE; OVERALL SURVIVAL; PBRM1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SETD2 GENE; SIDE EFFECT; THROMBOCYTOPENIA; VHL GENE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGNOSIS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES;

EID: 84887408241     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.183     Document Type: Article

References (10)

1. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722-731 (2013
2. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860-867 (2013
3. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010
4. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011
5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013
6. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259-3267 (2013
7. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: A metabolic disease. Nat. Rev. Urol. 7, 277-285 (2010
8. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384 (2011
9. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2011
10. Linehan, W. M. et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329-343 (2010